Cheng Guo Wang

US Patent:

6708045, Mar 16, 2004

Filed:

Apr 7, 2000

Appl. No.:

09/545228

Inventors:

Winston Hong Lieu - Holmdel NJ
Cheng Wang - Belle Mead NJ
David Kiley - Brick NJ
Charles Chia-Yi Pai - Cupertino CA

Assignee:

Mobicom, Inc. - Holmdel NJ

International Classification:

H04B 138

US Classification:

455557, 455418, 455558

Abstract:

A wireless terminal is described whose software are more easily upgradable than many in the prior art. Furthermore, the first illustrative embodiment of the present invention is an arrangement in which a user can easily: (1) upgrade the software in a wireless terminal, (2) change the parameters affecting the operation of the wireless terminal, (3) enable and disable features and options on the wireless terminal, (4) install software modules onto the wireless terminal and remove them, (5) reconfigure the reconfigurable hardware on the wireless terminal, (6) extract performance data from the wireless terminal for analysis and testing of the wireless terminal, and (7) load contact information (e. g. , names and associated telephone numbers, etc. ) onto the wireless terminal.

US Patent:

7041682, May 9, 2006

Filed:

Jul 2, 2003

Appl. No.:

10/612176

Inventors:

Neng-Yang Shih - North Caldwell NJ, US
Steven Wang - Jersey City NJ, US
Gregory Reichard - Ann Arbor MI, US
Dong Xiao - Warren NJ, US
Cheng Wang - Summit NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/445
C07D 211/56

US Classification:

514326, 546207, 546208, 546209, 546210, 546212, 546214, 544124

Abstract:

Disclosed are NKantagonists having the formula:.

US Patent:

7049320, May 23, 2006

Filed:

Dec 17, 2002

Appl. No.:

10/321687

Inventors:

Sunil Paliwal - Scotch Plains NJ, US
Gregory A. Reichard - Ann Arbor MI, US
Cheng Wang - Summit NJ, US
Dong Xiao - Warren NJ, US
Neng-Yang Shih - North Caldwell NJ, US
Juan D. Arredondo - Montclair NJ, US
Michelle Laci Wrobleski - Whitehouse Station NJ, US
Anandan Palani - Bridgewater NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/44
C07D 221/20

US Classification:

514278, 546 16, 546 19

Abstract:

A NKantagonist having the formula (I),.

US Patent:

40925200, May 30, 1978

Filed:

Dec 16, 1976

Appl. No.:

5/751241

Inventors:

Richard D. Holmes - Silver Spring MD
Cheng L. Wang - Silver Spring MD

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

H05B 102

US Classification:

219504

Abstract:

The leakage current thermostat is utilized in an electric heater assembly including a housing, a heating element mounted in the housing, electrical supply lines to the heating element and an electrically insulating material in contact with at least a portion of the heating element. The material has a temperature-resistance relationship such that the leakage current therethrough is a steep function of temperature. A leakage current thermostat includes a thermostat control circuit which is coupled to the supply lines and which is operative to control the current to the heating element in response to changes in the leakage current. The heating element is preferably formed by printed circuit techniques on a ceramic material which is affixed in a layer to a metal (conductive) base layer and the leakage current from the printed circuit element to the base is measured by the control circuit.

US Patent:

42989388, Nov 3, 1981

Filed:

Jan 28, 1980

Appl. No.:

6/115874

Inventors:

Cheng L. Wang - Silver Spring MD
Charles Soodak - Silver Spring MD
David Lohr - Ellicott City MD

Assignee:

Baxter Travenol Laboratories, Inc. - Deerfield IL

International Classification:

B01D 1300
G05D 706
G06G 757

US Classification:

364413

Abstract:

The backup control circuit is used with a main control circuit for a kidney dialysis machine and is operable upon failure of the main control circuit to operate with a predetermined time period to cause closing of a dialysate operate valve and opening of a dialysate bypass valve and/or stopping of a blood pump when an aberrant condition in the dialysate conductivity, temperature, flow or negative pressure are sensed and/or when an aberrant condition of the arterial or venous blood pressure is sensed and/or excessive leakage of blood into the dialysate is sensed. The backup control circuit includes control circuitry for controlling operation of the back-up control circuit, the circuitry having input contacts coupled to sensor inputs to the main control circuit. A time delay circuit has an input coupled to the control circuitry and is operable to initiate a timing cycle for the predetermined time period upon receiving an error signal from the control circuitry. Energizing and de-energizing circuitry has an input coupled to an output of the time delay circuit and outputs coupled to points in the main control circuit associated with coils for the dialysate operate valve, the dialysate bypass valve and the blood pump.

US Patent:

20200216860, Jul 9, 2020

Filed:

Sep 5, 2018

Appl. No.:

16/644411

Inventors:

- Tarrytown NY, US
Andrew J. MURPHY - Croton-on-Hudson NY, US
Cheng WANG - White Plains NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 15/86
C12N 9/22

Abstract:

The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichment RNA, or a sequence of a functional fragment or derivative thereof, wherein the enrichment RNA, or functional fragment or derivative thereof, is capable of enhancing inclusion of the gene-editing molecule mRNA, or functional fragment or derivative thereof, into a retroviral particle. The invention provides a method of producing the retroviral particles of the invention, the method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of retroviral particles.

US Patent:

20200196925, Jun 25, 2020

Filed:

Mar 5, 2020

Appl. No.:

16/810183

Inventors:

- New York NY, US
- Iowa City IA, US
Junyi Shang - New York NY, US
Zhixing Zhang - New York NY, US
Xuejun Wang - New York NY, US
Jaeyoung Yang - New York NY, US
Cheng Wang - New York NY, US
Pavana G. Rotti - Iowa City IA, US
John F. Engelhardt - Iowa City IA, US
Zhuang Hao - New York NY, US

Assignee:

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
DEPARTMENT OF ANATOMY AND CELL BIOLOGY - UNIVERSITY OF IOWA - Iowa City IA

International Classification:

A61B 5/145
G01N 33/74
G01N 27/414
H01L 21/02
H01L 29/16
H01L 23/38
A61B 5/1491
A61B 5/1477
A61B 5/00
H01L 51/05

Abstract:

A microdevice for monitoring a target analyte is provided. The microdevice can include a field effect transistor comprising a substrate, a gate electrode, and a microfluidic channel including graphene. The microfluidic channel can be formed between drain electrodes and source electrodes on the substrate. The microdevice can also include at least one aptamer functionalized on a surface of the graphene. The at least one aptamer can be adapted for binding to the target analyte. Binding of the target analyte to the at least one aptamer can alter the conductance of the graphene.

US Patent:

20200154684, May 21, 2020

Filed:

Jun 27, 2018

Appl. No.:

16/625168

Inventors:

- Tarrytown NY, US
Viktoria Gusarova - Pleasantville NY, US
Cheng Wang - White Plains NY, US
Christos Kyratsous - Irvington NY, US
Terra Potocky - Dobbs Ferry NY, US
Katherine Cygnar - New York NY, US
Joel Martin - Putnam Valley NY, US

International Classification:

A01K 67/027
A61K 49/00
C07K 14/705

Abstract:

Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.